Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.97−0.53 (-0.55%)
Close on Nov 17, 2026Market cap $10.89BP/E 28.3Yield –
Halozyme Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Halozyme Therapeutics's EV/EBITDA was 22.2× on Nov 11, 2026, against 12.7× a year earlier. Over the last 5 years it ranged from 12.0× to 35.3×, with a median of 19.8×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 22.2× | +10.2 |
| 2025 | Dec 31, 2025 | 12.0× | −3.2 |
| 2024 | Dec 31, 2024 | 15.2× | −3.7 |
| 2023 | Dec 29, 2023 | 19.0× | −16.2 |
| 2022 | Dec 30, 2022 | 35.1× | +18.7 |
| 2021 | Dec 31, 2021 | 16.5× | −126.3 |
| 2020 | Dec 31, 2020 | 142.8× | +102.5 |
| 2019 | Jan 31, 2019 | 40.2× | +3.8 |
| 2018 | Dec 31, 2018 | 36.4× | – |
See a number that looks wrong?